Chelidonine monohydrate (+)

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 苯并菲啶生物碱
• 英文名称: Chelidonine monohydrate (+)
• 英文别名: (1S,12S,13R)-24-methyl-5,7,18,20-tetraoxa-24-azahexacyclo[11.11.0.02,10.04,8.014,22.017,21]tetracosa-2,4(8),9,14(22),15,17(21)-hexaen-12-ol;hydrate
• 化学式: C20H21NO6
• 分子量: 371.4
• InChiKey: GDQZNUMWHOMFLJ-PHANBDLMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.51
• 重原子数：
  27
• 可旋转键数：
  0
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  61.4
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• Novel Chelidonine Derivatives, Methods for the Production Thereof, and Use Thereof For Producing Pharmaceutical Agents
  申请人：Salama Zoser B.

  公开号：US20080039483A1

  公开（公告）日：2008-02-14

  The invention relates to novel chelidonine derivatives, methods for the production thereof, the use of said compounds for the prevention, treatment, monitoring of the progress, and aftertreatment of diseases related to cell growth, cell differentiation, and/or cell division, especially tumors, and a kit comprising the inventive chelidonine derivatives.

  本发明涉及新型的赤茯苓碱衍生物，其生产方法，以及利用该化合物预防、治疗、监测进展和后期治疗与细胞生长、细胞分化和/或细胞分裂相关的疾病，尤其是肿瘤，并且包括该创新赤茯苓碱衍生物的试剂盒。
• NEUE CHELIDONIN-DERIVATE, VERFAHREN ZU IHRER HERSTELLUNG UND IHRE VERWENDUNG ZUR HERSTELLUNG VON PHARMAZEUTISCHEN WIRKSTOFFEN
  申请人：Salama, Zoser B. nat.rer.Dr.

  公开号：EP1685134B1

  公开（公告）日：2009-02-11
• METHODS AND RELATED COMPOSITIONS FOR THE TREATMENT OF CANCER
  申请人：Thompson Todd A.

  公开号：US20110224141A1

  公开（公告）日：2011-09-15

  A method of treatment and/or prevention of cancer comprises administering agents which cause increased intracellular granularity in cancer cells, at least in an amount sufficient to inhibit proliferation of such cells and preferably in an amount sufficient to lead to cancer cell death. The method is particularly directed to refractory cancer, particularly hormone refractory prostate cancer. The agents identified cause increased intracellular granularity in the cancer cells, and also convert adherent cancer cells to non-adherent cancer cells, leading to cancer cell death. Using the present invention, cancer cells undergo increased intracellular granularity at relatively low agent concentrations, while also inhibiting cell proliferation. Increased concentrations lead to conversion of adherent cancer cells to non-adherent cancer cells, then to cell death. While the exact mechanism of cancer cell degradation and death is not completely understood, the treated cancer cells, including refractory prostate cancer cells, give indications of cell death through an autophagic mechanism. Pharmaceutical compositions related to the presently disclosed methods are also disclosed.
• METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROLIFERATIVE VASCULAR DISORDERS
  申请人：Bischoff Joyce

  公开号：US20130029950A1

  公开（公告）日：2013-01-31

  The technology described herein is directed to methods and compositions for the treatment of proliferative vascular disorders, e.g. hemangioma. In some aspects, the methods and compositions described herein related to a mTOR inhibitor or nifedipine.
• US20140343347A1
  申请人：——

  公开号：US20140343347A1

  公开（公告）日：2014-11-20